Gene Therapy and FDA Regulations

by | Feb 14, 2020 | EU, EU MDR, FDA, Medical Devices, Pharmaceuticals, Regulatory

How does gene therapy fit into the FDA? Is it a medical device, a drug, or a combination product? What if gene therapy can cure a life-threatening disease? There are a lot of questions that can pop into your mind when you first hear “gene therapy”, but EMMA International is here to answer them.

Gene therapy is a field that is expected to rise in the near future. With the ability to treat or prevent diseases, gene therapy has finally caught the eyes of the FDA in a significant way.

The Center for Biologics Evaluation and Research (CBER) has approved both cellular and gene therapy products; however, the FDA just recently finalized a set of policies for the development and assessment of gene therapies. This clarified its views as it prepares for a coming surge of new treatments in diseases. By 2025, the FDA expects it will be reviewing and approving between 10 and 20 cell and gene therapy requests each year, which will also help advance the science. 1

Gene therapy is classified as a biological product that needs to be licensed through one of the two Biologics License Application pathways (BLA). BLA 351(a) is for a stand-alone biological product and BLA 351(k) is for “biosimilar” or “interchangeable” biological products. Both applications demonstrate that the biological product is manufactured, processed, packed, or held to meet standards designed to ensure that it continues to be safe, pure, and potent.2

The FDA offers expedited programs for regenerative medicine therapies for serious conditions or life-threatening diseases. Your gene therapy technique could be eligible for fast track designation, breakthrough therapy designation, RMAT (Regenerative Medicine Advanced Therapies) designation, accelerated approval, and priority review designation if it meets the correct criteria.3

The addition of effective gene therapy in the market creates a beneficial competition amongst other developers. This is helpful to the overall community in the result of potentially treating rare and serious diseases.

EMMA International can help you with all your gene therapy questions and FDA needs. Contact us at 248-987-4497 or email info@emmainternational.com to see how we can help you and your business!


1BioPharmDive (01/28/2020) FDA, expecting a gene therapy boom, firms up policies retrieved on (01/29/2020) from https://www.biopharmadive.com/news/fda-gene-therapy-guidance-sameness-durability/571225/

2FDA (February 2019) Principles of Premarket Pathways for Combination Products – Guidance for Industry and FDA Staff retrieved on (01/29/2020) from https://www.fda.gov/media/119958/download

3FDA (February 2019) Expedited Programs for Regenerative Medicine Therapies for Serios Conditions – Guidance for Industry retrieved on (01/29/2020) from https://www.fda.gov/media/120267/download

Emma International

Emma International

More Resources

De Novo Classification

De Novo Classification

A device can be registered for the De Novo pathway if there is evidence of the safety and effectiveness of the device and there is not a previously legally marketed predicate device1. When determining if your device can go through the De Novo process there are two pathways available to determine the device classification.
Abbreviated 510k submission

Abbreviated 510k submission

There are three types of 510K, Premarket Notifications, which can be submitted to the Food and Drug Administration (FDA) traditional, abbreviated, and special. Abbreviated and Special 510K submissions can be utilized when the submissions meet the certain factors presented by the FDA. When submitting an abbreviated 510K the submission must include the elements that are identified in 21CFR 807.87 for the information required in a premarket notification submission.
Is your product a medical device?

Is your product a medical device?

Many marketed products are classified as medical devices and you would not even know it. Medical devices range from latex gloves and tongue depressors to respirators and heart valves. To determine if the product is considered a medical device by the Food and Drug Administration (FDA) you will need to analyze if your product meets the definition of a medical device per the Food, Drug, and Cosmetic Act1.

Ready to learn more about working with us?

Pin It on Pinterest

Share This